Followed 120 TimesTop FollowedNASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free BLUE Stock Alerts $1.44 +0.02 (+1.41%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.37▼$1.5550-Day Range$0.91▼$1.7552-Week Range$0.88▼$5.53Volume7.95 million shsAverage Volume10.30 million shsMarket Capitalization$157.45 millionP/E RatioN/ADividend YieldN/APrice Target$6.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside344.6% Upside$6.40 Price TargetShort InterestBearish31.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 14 Articles This WeekInsider TradingSelling Shares$9,503 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.77) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector625th out of 947 stocksBiological Products, Except Diagnostic Industry114th out of 159 stocks 3.2 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.40, bluebird bio has a forecasted upside of 344.6% from its current price of $1.44.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted31.21% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bluebird bio has recently increased by 19.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 2.9 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for bluebird bio this week, compared to 5 articles on an average week.Search Interest87 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 93% compared to the previous 30 days.MarketBeat Follows120 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 422% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,503.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to decrease in the coming year, from ($1.77) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesMarch 6, 2024 | marketbeat.comBeam Therapeutics Bolts Higher on Gene Therapy Licensing Payments (BLUE)Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in placeMarch 2, 2024 | marketbeat.comMarketBeat Week in Review – 2/26 - 3/1 (BLUE)As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to investMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: February 29, 2024 | marketbeat.combluebird bio Stock Signals Potential to be a Multi-bagger (BLUE)Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could doFebruary 29, 2024 | marketbeat.combluebird bio Stock Signals Potential to be a Multi-baggerIt isn't often that you can find the right story at the right time to give you a good chance of multiplying your wealth; these so-called multi-bagger stocks get their name because their price sees a pop of more than 100%. Driven by a good story and other factors to help the jump happen.February 27, 2024 | marketbeat.combluebird bio: How to play LEAPS options for growth and incomeGene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRSP and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTX. CASGEVY made global headlines when it received FDA approval on December 8, 2023.However, on the same day, the FDA also approved LYFGENIA (lovotibeglogene autotemcel), which is another gene therapy treatment for SCD by bluebird bio NASDAQ: BLUE.February 27, 2024 | marketbeat.combluebird bio: How to play LEAPS options for growth and income Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDTFebruary 27, 2024 | marketbeat.combluebird bio stock is ripe for a 400% institutional short squeezeMaybe you are looking back at the 2020-2023 equity curve in your portfolio and are noticing an increasingly slowing upward trend. This is not your fault but rather the effects of the Federal Reserve (the Fed) raising interest rates, making ‘riskier' high growth plays less attractive to the overall market.March 18, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 27, 2024 | marketbeat.combluebird bio stock is ripe for a 400% institutional short squeezeBluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle inFebruary 26, 2024 | marketbeat.comIs CRISPR Therapeutics the NVIDIA of gene editing? (BLUE)CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approvMarch 18, 2024 | fool.comWhy Bluebird Bio Stock Flew Higher Than the Market TodayMarch 18, 2024 | marketwatch.comBluebird Bio Gets $175 Million in Financing from Hercules CapitalMarch 18, 2024 | finance.yahoo.combluebird bio Secures up to $175 Million Debt Financing with Hercules CapitalMarch 16, 2024 | finance.yahoo.comBLUE Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comBLUE Apr 2024 0.500 putMarch 16, 2024 | finance.yahoo.comBLUE Apr 2024 3.500 callMarch 16, 2024 | msn.comIs It Too Late to Buy CRISPR Therapeutics Stock?March 13, 2024 | fool.comIs Bluebird Bio Stock a Buy Now?March 13, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Shares Cross Below 200-Day Moving Average of $2.45March 13, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Shares Cross Below 200 Day Moving Average of $2.45March 12, 2024 | msn.comSickle Cell Patients Face a Tough Choice: Be Cured or Have KidsMarch 11, 2024 | finance.yahoo.combluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene TherapyMarch 5, 2024 | fool.comWhy Bluebird Bio Stock Dived Into the Red on TuesdayMarch 1, 2024 | markets.businessinsider.comStrong Market Potential for Bluebird Bio’s Lyfgenia Backed by High Demand and Differentiation FactorsFebruary 29, 2024 | msn.comBeyond approval: Patients pursue alternate paths to get rare disease treatmentsFebruary 25, 2024 | msn.comGene Therapies for Sickle Cell Disease: Hope, Access, and Cost Challenges ExploredSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today3/18/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$6.40 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+344.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-419.64% Pretax Margin-419.50% Return on Equity-34.32% Return on Assets-14.44% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.42 Sales & Book Value Annual Sales$3.60 million Price / Sales43.74 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.61Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$157.45 million OptionableOptionable Beta0.75 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsCellectisNASDAQ:CLLSMolecular PartnersNASDAQ:MOLNX4 PharmaceuticalsNASDAQ:XFORSangamo TherapeuticsNASDAQ:SGMOZura BioNASDAQ:ZURAView All CompetitorsInsiders & InstitutionsHBK Investments L PBought 1,500,000 shares on 3/14/2024Ownership: 1.372%Vanguard Group Inc.Bought 3,157,919 shares on 3/11/2024Ownership: 8.026%Wellington Management Group LLPBought 31,473 shares on 3/5/2024Ownership: 0.561%Goldman Sachs Group Inc.Bought 515,812 shares on 3/1/2024Ownership: 1.168%Virtu Financial LLCBought 229,542 shares on 2/26/2024Ownership: 0.210%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price target for 2024? 12 Wall Street analysts have issued 1-year price objectives for bluebird bio's shares. Their BLUE share price targets range from $1.02 to $13.00. On average, they anticipate the company's stock price to reach $6.40 in the next twelve months. This suggests a possible upside of 344.6% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2024? bluebird bio's stock was trading at $1.38 at the beginning of 2024. Since then, BLUE stock has increased by 4.3% and is now trading at $1.44. View the best growth stocks for 2024 here. Are investors shorting bluebird bio? bluebird bio saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 34,130,000 shares, an increase of 19.4% from the February 14th total of 28,590,000 shares. Based on an average daily trading volume, of 14,170,000 shares, the short-interest ratio is currently 2.4 days. View bluebird bio's Short Interest. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.03. The biotechnology company earned $12.40 million during the quarter, compared to analysts' expectations of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. The firm's revenue was up 17364.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.92) earnings per share. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). Who are bluebird bio's major shareholders? bluebird bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.03%), Vanguard Group Inc. (8.03%), Granahan Investment Management LLC (7.39%), Norges Bank (3.65%), Palo Alto Investors LP (3.05%) and Ghisallo Capital Management LLC (2.88%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLUE) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.